Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nothing. No updates on Libervant after approval. Now Anaphylm won’t be available for 2 more years.
It’s heading back to $2. Stop the bleeding please! drug approved but not ready to sell wtf is that? Next earnings will be brutal.
added. Great science and beautiful chart.
Offerings became bullish.. dont you know?
Is a bargain
Yessir absolutely
In other words you’re confident about this one from the clinical stage drug discovery sector
Not for long
AQST................................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
AQST...........................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
AQST.....................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
AQST..EXIT...MASSIVE PLAY
AQST...BREAKING 4 BUCKS...BEAST
AQST monster bio by the master trend
AQST.......................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
Just the beginning
Initiating this one. Fantastic turnaround by company leadership. Look at the ER from last night and see for yourself.
Toxic slobs is more like it.
On going S-3 shelf placement!
AQST
Aquestive Therapeutics Announces EPIPHAST II Trial Data For AQST-109; Says 'AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen Tmax of 22.5 minutes'
7:05 am ET September 27, 2022 (Benzinga) Print
AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes
AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration
Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen
End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter
Company hosts conference call at 8:00 am ET on September 27, 2022
me=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
Quite the hair cut since the delay. I bought in at 4.38 and will buy more if it drops further
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
205
|
Created
|
11/07/18
|
Type
|
Free
|
Moderators |